Hoda Z. Abdel-Hamid, MD, FAAN

  • Associate Professor of Pediatrics and Neurology
  • Director, Pediatric Neuromuscular Program, UPMC Children's Hospital of Pittsburgh
  • Director, Pediatric EMG Laboratory, UPMC Children's Hospital of Pittsburgh
  • Director, Pediatric MDA Clinic, UPMC Children's Hospital of Pittsburgh

Hoda Abdel-Hamid is a pediatric neuromuscular neurologist at the University of Pittsburgh. She is also the director of the pediatric MDA clinic at UPMC Children’s Hospital of Pittsburgh.

Abdel-Hamid collaborates on multiple multi-center research studies in the field of pediatric neuromuscular disease. She has a strong passion towards the care of children with chronic neuromuscular disease. Abdel-Hamid also acquired the necessary leadership skills to lead a big team of clinical collaborators that participate in the care of patients with chronic neuromuscular disease. As the director of the pediatric MDA clinic and the director of the neuromuscular program and EMG laboratory, Abdel-Hamid has access to many patients with chronic neuromuscular disease. She receives many consultations to help in achieving a diagnosis and coordinate the care of many patients with neuromuscular disease among other subspecialties. Abdel-Hamid helps coordinate the care between the different subspecialists including but not limited to pulmonology, cardiology, nutrition orthopedic and physical therapy.

Professional and Scientific Society Memberships

  • World Muscle Society, Member, 2009-Present
  • Child Neurology Society, Member, 2008-Present
  • American Association of Electrodiagnostic and Neuromuscular Medicine, Member, 2008-Present      
  • American Academy of Neurology, Member, 2003- Present
  • American Academy of Pediatrics, Member, 2000- 2003
  • American Medical Association, Member, 1999- 2002 
  • Egyptian Medical Syndicate, Member, 1996-Present

Education & Training

  • MD, Cairo University School of Medicine, 1995
  • Rotating Internship, Cairo University Hospitals, 1996-1997
  • Residency in Pediatrics, Cairo University Children's Hospital, 1997-1999
  • Residency in Pediatrics, Hurley Medical Center-Michigan State University, 1999-2002
  • Chief Resident, Hurley Medical Center-Michigan State University, 2001-2002
  • Residency in Neurology, University of Pittsburgh Medical Center, 2002-2003
  • Residency in Child Neurology, UPMC Children's Hospital of Pittsburgh, 2003-2005
  • Fellowship in Clinical Neurophysiology and Neuromuscular Disease, UPMC Presbyterian and UPMC Children's Hospital of Pittsburgh, 2005-2006

Selected Publications

Ozgur Dede, Abdel-Hamid HZ, Deeney VF. Spinal Deformity in Bethlem Myopathy Spine Deformity Volume 2, Issue 2, March 2014, 143–151.

Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, Alfano L, Gomez AM, Lewis S, Kota J, Malik V, Shontz K, Walker CM, Flanigan KM, Corridore M, Kean JR, Allen HD, Shilling C, Melia KR, Sazani P, Saoud JB, Kaye EM; Eteplirsen Study Group. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol. 2013 Nov;74(5):637-47

McDonald CM, Henricson EK, Abresch RT, Han JJ, Escolar DM, Florence JM, Duong T, Arrieta A, Clemens PR,   Hoffman EP, Cnaan A; CINRG Investigators. The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used.Muscle Nerve. 2013 Jul;48(1):32-54.

Henricson EK, Abresch RT, Cnaan A, Hu F, Duong T, Arrieta A, Han J, Escolar DM, Florence JM, Clemens PR, Hoffman EP, McDonald CM; CINRG Investigators. The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures.Muscle Nerve. 2013 Jul:48(1):55-67.

Kraker J, Abdel-Hamid H, Lacomis D, Neuromuscular pathology unknown. J Clin Neuromusc Dis 2010; 12:22-25.                                                                                                                                                         

A Maselli, J J Ng, J A Anderson, O Cagney, J Arredondo, C Williams, H B Wessel, H Abdel-Hamid and R L Wollmann. Mutations in LAMB2 causing a severe form of synaptic congenital myasthenic syndrome.  J Med Genet 2009;46;203-208.

Abdel-Hamid HZ, Oddis C, Lacomis D. Severe hydroxychloroquine myopathy. Muscle Nerve 2008; 38:1206-1210. 

Abdel-Hamid HZ, Lacomis D. Lambert-Eaton syndrome with thymic hyperplasia. J Clin Neurom Dis 2006;7 (5): 

Abdel-Hamid HZ, Wessel HB. Hereditary sensory motor neuropathy and pigmentary retinopathy. J Child Neurol 20:2005.

Abdel-Hamid HZ, Rezk P, Nawar MG, et al: Normal pregnancy outcome after inadvertent long-term exposure to gonadotrophin releasing hormone agonist. Mid-East Fert Soc J 2002; 7:231-233. 

Full Publication List via NIH PubMed »

Research Grants

Sarepta 4045-302, A Double-Blind, Placebo-Controlled, Multi-Center Study with an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients with Duchenne Muscular Dystrophy (PI), 2019-Present, Sarpeta Therapeutics, $1,749,361.

PTC, PTC124-GD-041-DMD (PI), 2019-Present.

Sarepta 5051-101, A Phase 1 Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Treatment (PI), 2018-Present, Sarpeta Therapeutics, $45,193.

Sarepta 5051-102, An Open-Label Extension Study for Patients with Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (PI), 2018-Present, Sarpeta Therapeutics, $119,469.

B5161002, A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy (PI), 2015-Present, Pfizer Pharmaceuticals.

B5161004, A multicenter, open-label extension study to evaluate the long-term safety of PF-06252616 in boys with Duchenne muscular dystrophy (PI), 2017-Present, Pfizer Pharmaceuticals.

PTC-124-GD-016-DMD, An open-label, safety study for previously treated Ataluren (PTC124) patients with nonsense mutation dystrophinopathy (PI), 2017-Present, PTC Therapeutics.